Humira has been the world’s best selling medicine since it arrived on the market in 2002. Now, it is finally getting ...

Cigna Healthcare’s medical care ratio increased to 82.2% in the first quarter compared with 79.9% in the first quarter of ...

Treating hidradenitis suppurativa is complex and often requires taking a number of medications, including antibiotics, ...

Sanofi’s development of an oral spin on Humira’s mechanism has hit a setback. | Sanofi’s development of an oral spin on ...

Alvotech faces challenges with potential tariffs and profitability, despite strong revenue growth and a robust pipeline. See ...

Humira (adalimumab) is a prescription drug that’s used to treat certain conditions, such as rheumatoid arthritis. Humira can cause side effects that range from mild to serious. Examples include ...

AbbVie is a popular stock with dividend investors for its high starting yield and continuous dividend increases. AbbVie is a ...

The price you pay for Humira (adalimumab) may depend on factors such as the form you take, whether you have health insurance, and the pharmacy you use. Financial assistance may be available to ...

Drugmaker AbbVie plans to invest more than $10 billion in domestic manufacturing and other capabilities over the next decade, ...

Analysts raise AbbVie price targets after strong Q1 results, driven by Skyrizi, Rinvoq growth and strategic moves in Parkinson's disease treatments.

AbbVie stock outperformed S&P 500 with a +16% to 9.41% return since November 2023, despite Humira revenue declining 38% to $8.99 billion. Immunology drugs Skyrizi and Rinvoq grew over 50% year ...

AbbVie stock climbs after Q1 earnings beat and 2025 EPS forecast raise; strong growth in immunology and neuroscience ...